Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly. Mazdutide has shown strong weight loss results in Chinese clinical populations, with Phase 3 data showing up to 17.4% weight loss at 48 weeks. It received approval in China in late 2025 for obesity treatment, making it one of the first dual agonists to reach market anywhere in the world.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Dual agonism of GLP-1 and glucagon receptors, similar to survodutide and pemvidutide. GLP-1 activation suppresses appetite and slows gastric emptying. Glucagon activation increases energy expenditure and hepatic fat oxidation. The dual mechanism targets both sides of the energy balance equation.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Weight management (approved in China)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- GI side effects (nausea, vomiting, diarrhea)
- Not yet approved outside China
- Potential blood sugar effects from glucagon component
- Long-term safety data still accumulating
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
Approved in China (late 2025) for obesity. Not yet submitted to FDA. Global Phase 3 trials ongoing. Represents the first approved GLP-1/glucagon dual agonist globally. US regulatory pathway unclear — may require separate US clinical program.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.